Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies by Davalli, Pierpaola et al.
Review Article
Targeting Oxidatively Induced DNA Damage Response in Cancer:
Opportunities for Novel Cancer Therapies
Pierpaola Davalli ,1 Gaetano Marverti ,1 Angela Lauriola ,2 and Domenico D’Arca 1,3
1Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
2Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
3Istituto Nazionale di Biostrutture e Biosistemi, 00136 Roma, Italy
Correspondence should be addressed to Domenico D’Arca; domenico.darca@unimore.it
Received 21 September 2017; Accepted 22 January 2018; Published 27 March 2018
Academic Editor: Paula Ludovico
Copyright © 2018 Pierpaola Davalli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cancer is a death cause in economically developed countries that results growing also in developing countries. Improved outcome
through targeted interventions faces the scarce selectivity of the therapies and the development of resistance to them that
compromise the therapeutic effects. Genomic instability is a typical cancer hallmark due to DNA damage by genetic mutations,
reactive oxygen and nitrogen species, ionizing radiation, and chemotherapeutic agents. DNA lesions can induce and/or support
various diseases, including cancer. The DNA damage response (DDR) is a crucial signaling-transduction network that promotes
cell cycle arrest or cell death to repair DNA lesions. DDR dysregulation favors tumor growth as downregulated or defective
DDR generates genomic instability, while upregulated DDR may confer treatment resistance. Redox homeostasis deeply and
capillary affects DDR as ROS activate/inhibit proteins and enzymes integral to DDR both in healthy and cancer cells, although
by different routes. DDR regulation through modulating ROS homeostasis is under investigation as anticancer opportunity, also
in combination with other treatments since ROS affect DDR differently in the patients during cancer development and
treatment. Here, we highlight ROS-sensitive proteins whose regulation in oxidatively induced DDR might allow for selective
strategies against cancer that are better tailored to the patients.
1. Introduction
Human cancer is the primary death cause in economically
developed countries and the second death cause in develop-
ing countries. Adoption of cancer-associated lifestyles as
smoking, physical inactivity, and “westernized” diets and
the increasing number of aging people are major causes for
cancer expansion [1]. Targeted therapy has improved the
outcome for specific cancer types; however, intrinsic or
acquired resistance to the therapies remains an inevitable
challenge for the patients [2–4]. Several features like cell
composition of the tumor, tumor microenvironment, and
drug efficiency lead tumor cells to overwhelm the therapies
through the same mechanisms that healthy cells utilize for
surviving under adverse conditions. In addition, many thera-
pies are scarcely selective for cancer cells and damage healthy
cells thus compromising the therapeutic effect [5–7]. Almost
all human tumors are characterized by genomic instability,
which essentially derives from deoxyribonucleic acid (DNA)
damage generated by reactive oxygen/nitrogen species
(ROS/RNS, usually referred as ROS), ionizing radiation, and
chemotherapeutic agents, besides occasional genetic muta-
tions, so that DNA damage is direct and indirect target of a
wide number of anticancer treatments [8–11]. Eukaryotic
cells have developed a sophisticated signaling-transduction
mechanism, named DNA damage response (DDR), that
maintains cell genome integrity by acting as an efficacious
network. DDR can detect DNA lesions and arrest the cell
cycle both temporary (checkpoint control activation) and
permanently (senescence) or promote cell death (apoptosis).
DDR sets cell fate depending on mode and level of DNA
damage after comparing its severity and cell potentiality to
survive. Aberrant repair mechanisms, mutations, and poly-
morphisms of genes involved in DNA repair contribute to
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human cancer onset, development, and progression [12–15].
DDR defects that are detectable in human tumors allow
classifying the patients for appropriate therapy. Tumor cells
often shift their ratio between DNA damage and DNA repair
activities in favor of repair that leads to stabilize DNA lesions,
as the repairing system cannot identify gene mutations. The
lesion extent may exceed the repairing capability of the cell
and generate resistance to DNA-targeted therapies [16–18].
Mechanism-based-targeted therapies are preferentially
administered as single-target therapies often induce resis-
tance through restoring basal cancer pathways [19–21]. Oxi-
datively induced DDR has aroused increasing interest since
when ROS are no more considered causing exclusive molecu-
lar damage or palliative effect against anticancer drugs. ROS
together with related molecules and enzymes contribute to
physiological functions and pathological alterations of DDR.
Oscillations of the redox equilibrium under the cell death
threshold can affect the stringency of DDR through modulat-
ing its pathways andmechanisms [22–24]. ROS participate to
the complex crosstalk of DDR and autophagy that contributes
to treatment resistance of cancer cells and their subsequent
regrowth through the DNA repair mechanisms [25–29].
Depending on their level, ROS coordinate intracellular redox
signaling by acting as messengers in both healthy and cancer
cells, although through different pathways. The imbalance
between ROS/RNS production and elimination favors their
accumulation, subjecting both healthy and cancerous cells
to the oxidative/nitrosative stress (collectively named oxida-
tive stress, OS). Cancer cells proliferate in a constitutive OS
state, as their hallmark, that may generate resistance to
ROS-based anticancer interventions when the antioxidant
system of the cell is proportional to its OS level or evolve
towards cell death when ROS are subjected to spontaneous
or therapeutically induced further increase [30–35].
Here, we briefly prospect possible points of therapeutic
intervention in oxidatively induced DDR regarding ROS
homeostasis involvement that are under investigation as
mechanism-based therapeutic strategies to counteract the
human cancer.
2. ROS Homeostasis
2.1. Production of ROS and RNS. The oxidative metabolism
in mitochondria constantly produces a flux of reactive oxy-
gen species (ROS) and a flux of reactive nitrogen species
(RNS) as oxidative phosphorylation by-products. The pro-
duction is estimated on average 1-2% of total rate of oxygen
consumption in healthy human body. ROS/RNS are usually
named free radicals since they are the most important classes
of the free radical family in the majority of living organisms.
Free radicals contain an atom or a molecule with one or more
unpaired electrons that make them highly reactive, able to
bind other radicals or oxidize molecules that they contact.
Free radicals share a short life and a generation of chain reac-
tions that ultimately lead to cell structure damage. ROS com-
prise the singlet oxygen (½ O), the superoxide anion radical
(O2⨪) and its metabolites, as the very toxic hydroxyl radical
(•OH), and the nonradical hydrogen peroxide (H2O2) that,
in the presence of redox active metals, is partially reduced
to (•OH), by Fenton reaction [36]. The mitochondrial respi-
ratory chain leaks electrons causing partial oxygen reduction
to O2⨪, which is spontaneously, or by superoxide dismutase2
(SOD2), rapidly transformed into H2O2. Also, peroxisomal
NADPH oxidases (NOXs) are implicated in electron transfer
from intracellular NADPH to oxygen generating O2⨪ that is
converted into H2O2 by superoxide dismutase3 (SOD3). The
overall H2O2 is turned into reactive
•OH radicals. RNS were
derived from the very dangerous peroxynitrite (ONOO−)
generated by O2⨪ and nitric oxide (•NO), a highly reactive
gaseous molecule, but not a radical, soluble in water and dif-
fusible across cell membranes. The reaction is catalyzed by
NO synthases (NOS1–3), a family of constitutive or inducible
enzymes with different tissue distribution utilizing arginine
and NADPH. •NO competes with SOD by directing O2⨪
towards ONOO−, rather than H2O2. NO-derived oxidants
are endowed with cellular antimicrobial action and act with
ROS contributing to establish oxidative conditions [37, 38].
2.2. Antioxidants (ROS Scavenging System). Living organisms
have evolved enzymatic and nonenzymatic pathways that
prevent oxidative damage to essential macromolecules,
including proteins and nucleic acids. The pathways are mod-
ulated by several protein-based sensory, while regulatory
modules ensure a rapid and appropriate response [39]. Per-
oxisomal catalase, SODs, glutathione peroxidase, and ascor-
bate peroxidase are antioxidant enzymes that remove O2⨪,
H2O2, and peroxides in cell districts, acting as highly efficient
antioxidant systems that protect cellular components by var-
iable extent. The enzymes act in concert with other proteins
as peroxiredoxins [40–43], thioredoxins (Trx) [44], glutare-
doxins (Grx) [45], and metallothionein [46–48] and with
low molecular weight, nonenzymatic antioxidants as ascor-
bate, glutathione [45, 49], tocopherol, carotenoid, and mela-
tonin [50–53]. The oxidative signal is essentially reversed by
two potent antioxidant systems the Trx/Trx reductase and
Grx/Grx reductase, which reduce disulfides to free thiol
groups at the expense of NADPH depletion. Antioxidant sys-
tems contribute to scavenge excessive ROS, thus finely con-
trolling their levels and restoring the pools of reduced
proteins and lipids (Figure 1).
2.3. ROS/RNS Effects. ROS/RNS exert different effects on the
same targets, depending on cell type, with the exception of
•OH and ONOO− that are always associated to plain toxicity.
The basal oxidation level that is necessary for correct cell via-
bility and functions requires a redox homeostasis mecha-
nism. Radical fluctuations are strictly controlled through
their continuously balancing in, for instance, increased
energetic demand, which intensifies electron flux through
mitochondria, or aging, which decreases mitochondrial
efficiency. Exogenous ROS/RNS sources, as oxidases and
oxygenases, infrared and ultraviolet radiations, dietary nitro-
samines, or chemotherapy agents [21], may contribute to
redox homeostasis changes. Final effect of ROS/RNS, from
now simply referred as ROS, is not exclusively determined
by cellular concentration of each species but also by balance
between different species, that is, H2O2 versus O2⨪. Indeed,
O2⨪ from mitochondria may drive signaling pathways in
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cancer onset, development, and amplification. ROS trigger
thiol oxidation, glutathionylation, nitrosylation, and carbon-
ylation on specific proteins and enzymes, which conse-
quently act as signal mediators in cell metabolism and
signaling, even if the exact mechanisms have to be clarified
[38, 54, 55]. Both cytosolic and nuclear proteins are ROS tar-
get containing ROS-sensitive cysteine residues that play reg-
ulatory rather than structural roles. These cysteines react as
molecular switches that transduce redox signals, conferring
redox activity to the proteins through their thiol groups.
After undergoing oxidative modification and generation of
S-hydroxylated derivatives, protein conformation/function
is modified by reacting with other cysteines that generate
either intra- or intermolecular disulfides, the last promoting
complexes to conduct new functions. Redox-activated pro-
teins act as intracellular redox sensors that allow for ROS
properly adapting to their functions in the cellular redox
equilibrium [21, 56]. Actually, these sensors result useful
for studying pathogenesis and progression of multiple dis-
eases [39, 55]. In particular, physiological trace levels of
H2O2 act as both sensor and second messengers, being able
to cross membranes, and induce specific signal transduction
pathways in the cell [55]. ROS contribute to cell homeostasis
as “second messengers” by modulating the activities of key
regulatory molecules, including protein kinases, phospha-
tases, G proteins, and transcription factors. Periodic oscilla-
tions in the cell redox environment regulate cell cycle
progression from quiescence (G0) to proliferation (G1, S,
G2, and M) and back to quiescence, as a redox cycle. A loss
in the redox control of cell cycle could lead to aberrant pro-
liferation, a hallmark of various human pathologies [57].
ROS role is continuously delineated in a variety of physio-
pathological conditions including cell growth, proliferation,
differentiation, aging, senescence, and defense against infec-
tious agents during inflammatory responses [58, 59].
2.4. Oxidative Stress. Excessive ROS (O2⨪, •OH, and H2O2)
or RNS (peroxynitrites and nitrogen oxides) and their reac-
tive metabolites may be derived from imbalance between oxi-
dant generation and removal by antioxidants that disrupts
the redox homeostasis. The condition, named oxidative/
nitrosative stress (OS/NOS, simply referred as OS), is poten-
tially harmful because increasing levels of excessive radicals
induce improper signaling or oxidation of the main essential
cell molecules. Bases in nucleic acid, amino acid residues in
proteins, and fatty acids in lipids show different susceptibility
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Figure 1: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) balance is critical in maintaining cellular homeostasis. Excessive
levels of ROS (O2⨪, •OH, and H2O2) and/or RNS (ONOO−) affect the redox homeostasis, inducing oxidation of cellular nucleic acids,
proteins, and lipids. The cells activate several antioxidant systems to maintain the intracellular redox equilibrium, including an enzymatic
system (ascorbate peroxidase, glutathione peroxidase, peroxisomal catalase, and SODs) that works in concert with other nonenzymatic
proteins (glutaredoxins, metallothionein, peroxiredoxins, and thioredoxins) and an nonenzymatic system (ascorbate, carotenoid,
glutathione, melatonin, and tocopherol). In addition, autophagy is a very sensitive antioxidant system. NOXs =NADPH oxidases; cys-
SH= cysteine-SH.
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to OS that allows for a finely organized signaling system. OS
consequences depend on cell type so that it is hard to clearly
differentiate OS and redox signaling. Cellular OS level mod-
erately overcoming cellular antioxidant level may provide
selectivity for specifically targeted molecules and constitute
a signaling mechanism, even after generating specific irre-
versible alterations of definite molecules [60–62]. Metabolic
changes from cellular OS include (a) reduced ATP concen-
tration, possibly caused by damaged mitochondria, (b) deac-
tivated glyceraldehyde-3-phosphate dehydrogenase, which
causes glycolysis inhibition, (c) increased catabolism of ade-
nine nucleotides, (d) enhanced ATP consumption due to
the active transport of oxidized glutathione, (e) increased
cytoplasmic calcium concentration from deactivated calcium
pumps, (f) cell membrane depolarization, possibly due to
deactivation of K, Ca, and Na channels, resulting in increased
cell membrane permeability, and (g) decreased glutathione
level and ratio between reduced and oxidized glutathione.
Another dangerous event is the generation of oxidized gluta-
thione in various connections with xenobiotics, products of
lipid peroxidation, or proteins present in the cell. Increased
ATP consumption occurs in disposing such products outside
the cell that also contributes to reductions in cellular glutathi-
one [63, 64]. Generally, excessive ROS irreversibly damage
structures of main macromolecules, membranes, and organ-
elles and hamper signal mediators activity, thereby represent-
ingaprimarydamage source inbiological systems. Irreversibly
oxidized biomolecules are essentially cleared from cells
through the autophagic process that is consequently consid-
ered a very sensitive antioxidant system. Autophagy is a con-
verging point of different inputs and underlies cell responses
to stressful conditions affecting cellular homeostasis, from
biomolecules integrity to cell viability. OS acts as a vital stim-
ulus to sustain autophagy, with ROS being one of the main
signal messengers, thus autophagy and ROS coordinate to
maintain cellular homeostasis [25, 65]. Although the mecha-
nism by which ROS activates autophagy remains unclear, an
essential autophagy-associated protein Atg4 has been shown
to be under redox control. S-glutathionylation of the AMP-
activated protein kinase AMPK may also contribute to its
activation by H2O2 exposure, which allows for autophagy
progression [28].
2.5. Oxidatively Damaged DNA. The threat of cell molecule
oxidation is a consequence of life in an oxygen-rich habitat
that differently challenges molecule integrity and cell viability
through the intermediate activity of homeostatic processes,
mainly based on repair and degradation. Millions of DNA-
damaging lesions occur every day in each cell of our bodies
due to various stresses. Among which OS represents a major
portion as it may induce approximately 104 DNA lesions per
cell of an organism per day. OS mediates the damage upon
different insults such as ultraviolet, X- and γ radiations, pol-
lutants, poisons, or endogenous disequilibria as metabolic
imbalance that produce different and characteristic types of
lesions. The lesions are particularly significant since they
interfere with DNA replication that generates mutations,
unless repaired in an error-free process, and alter the expres-
sion of protein, including transcriptional factors, and
consequently signaling pathways and cellular behavior.
Among endogenous and exogenous ROS/RNS, the O2⨪ is
considered as a main candidate, responsible for genetic insta-
bility and malignant transformation. Oxidative DNA damage
on bases of nucleic acid is repaired to a certain extent for
maintaining the genome integrity, as evidenced by the
DNA repair systems of the cell that are outlined below, but
the damage may also escape the repair systems [66–68]. Both
nuclear (nDNA) damage and mitochondrial DNA (mtDNA)
damage are particularly significant as it can interfere with
replication to generate lasting mutations [63, 69]. Although
mitochondria possess quality control systems that include
antioxidant enzymes, mtDNA is more susceptible to oxygen
damage than nDNA, possibly due to (a) lack of nuclear pro-
teins associated with mtDNA, which could protect it from
damage, (b) less elaborate and efficacious repair system than
nDNA repair machinery, and (c) the proximity of the respi-
ratory chain where ROS/RNS are continuously generated.
Two theories attempt to explain the cause of DNA damage:
by the first, the damage results from a site-specific Fenton
reaction, that is, the generation of a hydroxyl radical in the
reaction of transition metal ions present in DNA with
H2O2 and by the second theory, OS increases intracellular
calcium concentration, which in turn activates nucleases
digesting DNA [70, 71]. Reactions causing DNA damage
and their breakdown products are a multitude exemplified
by (a) lesions generated by ½ O as nitrogen modifications
in DNA bases, in preference guanine, producing 8-oxo-7,8-
dihydroguanine (8-oxoG) and (b) •OH that adds double
bonds and abstracts a H atom from methyl groups in DNA
bases, producing molecules as 5-hydroxymethyl-uracil, C8-
OH-adduct guanine radical, and 8-hydroxyguanine; •OH
targeting C atoms of DNA sugar moiety by abstracting a H
from each C–H bond of 2′-deoxyribose, generating various
molecules, as 2-deoxypentose-4-ulose, 2-deoxypentonic acid
lactone, erythrose, 2-deoxytetradialdose, and glycolic acid
[72, 73]. In complex, the above lesions cause base and
tandem base modification, leading to DNA intrastrand cross-
links, DNA-protein crosslinks, mismatched pairs with dam-
aged bases, stalled DNA replication forks, clustered lesions,
and single- and double-strand breaks (SSB-DSB). SSB are
due to modified DNA bases and abasic sites, apurinic/apyri-
midinic sites, caused through purine and pyrimidine base
damage as well as sugar moiety damage. SSB are the most
common lesions that result from genotoxic insults by endog-
enous ROS [17]. Electrophilic molecules or intrinsic DNA
instability or inhibition of topoisomerase, which traps
cleaved DNA intermediates, may cause SSB. If not repaired,
the damaged site may be bypassed by incorporating a mis-
matched deoxynucleotide during DNA replication. Many
oxidative base lesions in DNA are mutagenic, provoking
structural alterations, including transversions: G/T or A/C,
or overall conformational changes, which may affect tran-
scription and/or replication processes, leading to chromo-
some deletions with lethal effects. The most common base
oxidations 8-oxoG mispair with adenine (8-oxo-G:A) and
5-hydroxycytosine with thymine thus causing replication
stress. The accumulated lesions lead to pathological pro-
cesses, as they result cytotoxic by causing mitochondrial
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dysfunction, mutagenic by causing genetic instability, and
finally oncogenic. Also, the marker of inflammation 8-
nitroguanine is considered a potential mutagenic [74]. A
key cellular response to oxidative damage is the signaling
through the JNK pathway. Depending on intensity and dura-
tion of the damage signal, this pathway leads to distinct
alternative responses including DNA repair, antioxidant pro-
duction, or cell death. When damage overcomes cell repair-
ing systems, the damage signal (i.e., excessive ROS and
products) drives JNK pathways toward proliferation arrest
and or cell death that both play a fundamental role in cell
homeostasis maintenance. These responses are highly rele-
vant to cancer therapy, as tumors are often under OS that
produces elevated JNK levels, and therapy often involves
inducing DNA damage with the intention of driving cell
death [75]. Generally, oxidative DNA damage is enhanced
in tumors where increased metabolism, oncogenic signaling,
and mitochondrial dysfunction produce 100-fold more 8-
oxoG than in healthy tissues. Inflammation promotes carci-
nogenesis and generates ROS in tumor cell and its microen-
vironment that add to a high level of spontaneous DNA
base deaminations. A consequent base mispairing is gener-
ated that is potentially mutagenic if not rapidly and efficiently
repaired. Ever increasing ROS levels lead cells to death
(apoptosis). This feature is exploited to exert therapeutic
effect against cancer by therapy tailored to augment cellular
ROS level. Oxidative damage is believed a potential double-
edged sword in cancerogenesis and ROS-based anticancer.
Although at low and moderate levels, ROS affect some of
the most essential mechanisms of cell survival such as prolif-
eration, angiogenesis, and tumor invasion, at higher levels,
these agents can expose cells to detrimental consequences
of OS including DNA damage and apoptosis that result in
therapeutic effects on cancer. Understanding the new aspects
on molecular mechanisms and signaling pathways modulat-
ing creation and therapy of cancers by ROS is critical in the
development of therapeutic strategies for patients suffering
from cancer [30, 76]. Antioxidants protect against genotoxic
agents and alleviate their effects by decreasing primary DNA
damage that reduces risk of mutation and tumor initiation.
ROS enhances the localization of metallothionein (MT) in
the nucleus where MT is more efficient than the reduced glu-
tathione in protecting DNA from ROS attacks [76, 77]. The
enzyme human mutT homolog detoxifies oxidized nucleo-
tides thus potentially preventing 8-oxoG-induced mutations.
It particularly eliminates 8-oxo-7,8-dihydro-2′-deoxyguano-
sine triphosphate that detoxifies oxidized nucleotides
through its pyrophosphatase activity which is a potential tar-
get in cancer therapy [78, 79] (Figure 2).
2.6. DNA Repair in Oxidatively Damaged DNA. Cells have
evolved several DNA repair pathways to deal with DNA
damaged by OS that sense DNA lesions and process them
into appropriate structures for DNA damage response
(DDR) activation. DNA lesions and corresponding repair
mechanisms have been reviewed by Curtin [17] and Chatter-
jee and Walker [80]. A part from the simplest form of DNA
repair that is the direct reversal of the lesion, the cells are
equipped with a variety of distinct, although partially
compensatory, DNA repair mechanisms, each addressing a
specific type of lesion. There are multiple types of DNA dam-
age in humans as well as distinct but interrelated DNA repair
mechanisms. Dysregulation of the mechanisms plays a key
role in cell genomic instability. Among the repair pathways,
tolerance mechanisms are also comprised as the translesion
synthesis (TLS) that is composed by specialized DNA poly-
merases and regulatory proteins able to confer viability in
the presence of unrepaired damage. Examples of the most
common mechanisms to repair oxidatively damaged DNA
regard the repair of modified bases by direct repair and base
excision repair (BER) [81, 82], base mismatch repair by mis-
match repair pathway, intrastrand crosslinks (ICL) by a com-
plex repair that involves Fanconi anaemia pathway (FA),
nucleotide excision repair (NER) [83, 84], TLS and homolo-
gous recombination (HR) [85], DNA-protein crosslinks by
ICL repair and NER, stalled replication forks by HR, NER,
and FA, single-strand breaks (SSB) by BER and HR, double
strand breaks (DSB) [85, 86] by HR, and nonhomologous
end joining (NHEJ) [87, 88]. The most deleterious lesions
produced by many chemotherapeutic agents that block repli-
cation and transcription are represented by ICLs. NHEJ is
thought to be the primary means of repair for therapeutically
induced DSBs resulting from ROS-inducing anticancer treat-
ments. Selective DNA repair inhibitors are considered effica-
cious in cancer therapy with minimal host toxicity [89–91]
(Figure 2).
3. DNA Damage Response (DDR)
The exogenous and endogenous insults upon human DNA
result in accumulation of DNA damage that alters the chro-
matin environment besides increasing the mutagenic and
immunogenic properties of the DNA [92–94]. The overall
alterations possibly lead to physiological processes as aging
and senescence or impact health and modulate disease states
[95–97]. DNA damages induce and coordinate a complex
signal-transduction network composed by several pathways,
collectively named DNA damage response (DDR), that con-
nects the DNA damage signaling to the cell cycle checkpoints
maintaining cell homeostasis and functions while the dam-
age is repaired. DDR prevents DNA duplication, cell division,
and cell cycling, by arresting transcription process, to pre-
serve genome stability and promote cell survival in front of
both reparable or irreparable lesions [98]. If the damage is
severe and irreparable, the cell cycle arrest is followed by cell
death programs (apoptosis/necrosis) or senescence that elim-
inate damaged cells and avoid their multiplying. DDR initi-
ates through phosphorylation-driven signaling cascades
that sense the DNA damage, being regulated by mediators,
and activate downstream effectors that finally determine the
cell fate. It has been evidenced a set of 450 genes encoding
proteins integral to DDR, among which a “core” group of
proteins acts in different steps with some overlapping func-
tions: (a) specialized “sensor proteins” detecting the damage;
(b) transcription factors proceeding as “transducer proteins”
upon their activation; and (c) “effector proteins” that are
recruited by mediators. Other proteins organize and regulate
a spectrum of processes that integrate DDRwith the cell cycle
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progression allowing for the DNA repair [99, 100]. Each step
in DDR is tightly regulated by reversible posttranslational
modifications including phosphorylation, ADP-ribosylation,
methylation, acetylation, ubiquitylation, sumoylation, and
neddylation. Oxidatively induced DNA damage results in
robust activation of three protein kinases that belong to the
phosphatidylinositol-3-kinase- (PI-3-kinase-) related kinases
of the PI-3-kinase/Akt pathway: (i) ataxia telangiectasia-
mutated kinase (ATM); (ii) ATM- and Rad3-related kinase
(ATR); and (iii) DNA-dependent protein kinase catalytic
subunit (DNA-PKcs). The kinases are central components
in DDR triggering and act together with the DNA repair
machinery to maintain cell genome integrity [101–103].
ATM and ATR are activated through auto-phosphorylation
as apical regulators of the response to DSBs and replication
stress, respectively, with overlapping but nonredundant
activities. A functional crosstalk between the major ATM/
ATR pathways controls and coordinates DDR by affecting
DNA replication, DNA repair, DNA recombination, mRNA
transcription, and RNA processing, as well as protein metab-
olism and cell cycle. DNA-PKcs interacts with the DNA-
binding Ku 70/80 heterodimer to originate the DNA-PK
complex, a key regulator in NHEJ pathway that repairs the
DSB damage. The first signal transduction wave is conducted
by ATM/ATR phosphorylation that acts as DNA damage
sensor and transducer. ATM activation is mediated through
the Mre11-Rad50-NBS1 (MRN) complex that binds ATM
through multiple protein-protein interactions, recruits
ATM to DNA lesion as inactive dimer, and unwinds DNA
ends to activate ATM. The complex MRN-ATM is located
at the damaged DNA foci marked by histone γ-H2AX that
is phosphorylated by the complex and regulates various
downstream mediators to coordinate the DDR. Despite their
distinctive individual activities, ATM, ATR, and DNA-PKcs
share many overlapping substrates and roles in the regulation
of the cell cycle checkpoints as primary or secondary
responders to several DNA lesions. Upon their activation,
ATM/ATR phosphorylate the checkpoint kinases CHK2
and CHK1, respectively, that acting as effector proteins, and
phosphorylate the A, B, and C isoforms of the Cdc25s
phosphatases. The phosphatases lead to inactivate cyclin-
dependent kinases (CDK) and arrest cell cycle either at G1/
S or G2/M transition, depending on which CDK is inhibited.
CHK1 has a double role in CDK1 inactivation, by directly
inhibiting Cdc25 and activating the tyrosine kinase Wee1,
which specifically inhibits CDK1. Cdc25s control the cell
cycle via specific checkpoints in physiological conditions as
well as in response to DNA damage. These phosphatases
transmit the damage signaling to effectors such as the tumor
suppressor p53, a key molecule interconnecting DDR, cell
cycle checkpoints, and cell fate decisions in the presence of
genotoxic stress; p53 leads to cell cycle arrest or senescence
or apoptosis depending on the damage extent and the cellular
context. Inactivating mutations in TP53 gene and other genes
involved in DDR potentiate cancer development and influ-
ence cancer cell sensitivity to anticancer treatments [21]. A
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Figure 2: Oxidative stress (OS) causes DNA damage with consequent activation of DNA repair pathways. OS induces DNA damages by two
major reactions: increase of the intracellular calcium levels, activating DNA digestion, and Fenton reaction. DNA damage triggers the main
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novel genomic stress sensor in the DDR pathway is the AMP-
activated protein kinase (AMPK) that is physically associated
with the mitotic apparatus and participates in cytokinesis.
AMPK has been previously known as a metabolic stress sen-
sor, able to control cellular growth and mediate cell cycle
checkpoints in cancer cells in response to low energy levels.
AMPK is a key effector of the tumor suppressor liver kinase
B1 (LKB1), which inhibits the cell growth mediator mamma-
lian target of rapamycin (mTOR) and activates checkpoint
mediators such as p53 and cyclin-dependent kinase inhibi-
tors p21 (cip1) and p27 (kip1). Ionizing radiation and che-
motherapy activate AMPK in cancer cells to mediate the
signal transduction downstream of ATM that activates p53-
p21 (cip1)/p27 (kip1) and inhibits mTOR. AMPK works as
a convergence point of metabolic and genomic stress signals,
which (i) controls the activity of growth mediators, (ii) prop-
agates DDR, and (iii) mediates the antiproliferative effects of
common cytotoxic cancer therapy such as radiation and
chemotherapy. This highlights the importance of targeting
AMPKwith novel cancer therapeutics [104]. Also, it is worth-
while mentioning that the Wnt/beta-catenin signaling path-
way, which is pivotal for modulating cell fate, proliferation,
and apoptosis, can activate oxidatively induced DDR by reg-
ulating various proteins as histone γ-H2AX, p16INK4a,
p53, and p21 [105]. Irreparable DNA lesions trigger elimina-
tion of damaged cells by apoptotic pathways like the autoph-
agy form named “mitophagy” that leads to lysosomal
degradation of damaged mitochondria [106, 107]. ATM links
DDR to mitophagy induction by activating the LKB1/AMPK
pathway, which in turn activates TSC2 by phosphorylation,
thereby inhibiting mTORC1 and removing its inhibitory
effect on mitophagy. Since autophagy contributes to clearing
the cells of all the irreversibly oxidized biomolecules, it might
be included both in the antioxidant system and the DNA
damage repair system. Interestingly, it has been recently
shown that some DNA repair enzymes can also activate and
regulate the autophagy process [108, 109]. The indicated
DDR pathways are involved in repairing oxidative DNA
damage in healthy as well in cancerous cells, although follow-
ing a different organization. Cancer cells frequently show sev-
eral mutated molecules that lead to a reduced DDR activity
thus facilitating the generation of further mutations and
enhancing the cancer progression. Understanding the mech-
anism by which DDR is regulated under genotoxic stress
should help improving the clinical outcomes [21] (Figure 3).
4. ROS-Sensitive Proteins Involved in DDR
Since when Rotman and Shiloh firstly proposed that ATM
may act as a direct sensor and responder in cell OS and
damage, accumulating body of studies has been reported.
Attention is now focused on identifying the molecular contri-
butions of ATM, ATR, and DNA-PKcs in the interplay
between the DDR mechanism and the redox asset that com-
prehends the redox signaling, besides the oxidative DNA
damage generated during the OS conditions [110, 111].
Indeed, several oxidative reactions contribute to redox sig-
naling through finely modulating DDR at different levels, a
part from causing oxidative genotoxic lesions. Interestingly,
many proteins involved in DDR are endowed with a high
number of cysteine residues (indicated in parenthesis) as
exemplified by Chk1 (9), Wee1 kinase, a specific CDK1
inhibitor (12), Chk2 (13), Plk1 that allows cell cycle progres-
sion recovery after its arrest (13), and caspase 2 that is
involved in apoptosis and is inhibited during G2 arrest by
Chk1 (18). These ROS-sensitive proteins undergo modifica-
tions in their structure and function through cysteine residue
oxidation and disulfide generation depending on the cellular
ROS levels. In addition, some of these proteins activate path-
ways as p53 and p21 pathways, which finally lead to cell ROS
level regulation. Through this loop mechanism, ROS contrib-
ute both to maintain the cell redox equilibrium and calibrate
the DDR reactions [21, 112]. ATM is an OS-sensitive protein
in which specific cysteine residues originate interprotein dis-
ulfides in human cells, upon being oxidized by ROS, thus
resulting as an active homodimer. ATM is also activated
through phosphorylation, as previously mentioned. The sub-
strates phosphorylated by ATM are different following the
MRN- or the OS-dependent activation, suggesting a different
substrate specificity in the two conditions. While ATM phos-
phorylation initiates DDR in the nucleus, disulfide homodi-
mer activates specific transcription factors in the cytosol,
thereby leading to induction of antiapoptotic and prosurvival
proteins. Through ATM activation, ROS lead to the recruit-
ment of important proteins involved in DDR, including γ-
H2AX histone and p53. The roles and localizations of ATM
might be due to the presence of separate pools or ways of
activation of ATM, or both the conditions that differently
sense the cellular ROS levels. As very often OS and DNA
damage overlap, the above conditions might collaborate in
protecting the damaged cells from apoptosis while their
DNA is repaired. It is difficult to discover the degree of over-
lap between substrates that are phosphorylated by ATM fol-
lowing DNA damage and substrates that are phosphorylated
during OS, because the two ATM activities are usually
exposed to both the conditions simultaneously. For instance,
in anticancer treatments by ionizing radiations, both ROS
production and DSB lesions are induced. The roughly 700
ATM targets that have been evidenced by a proteome analy-
sis as probable targets in both DNA repair and oxidation
pathways highlight a complicated interplay between oxidized
ATM and DSB-activated ATM. The targets are mostly com-
prised of proteins involved in DNA replication, repair, and
cell cycle control, as well as proteins affecting insulin signal-
ing. This suggests that ATM may also function through reg-
ulation of metabolic signaling. In conditions that separate
DNA from OS damage effects, only a subset of ATM targets
that are usually phosphorylated in DDR is also phosphory-
lated in OS conditions. Now, ATM inhibitors of DDR mech-
anism are investigated as inhibitors of ATM redox functions.
An ATM variant has been identified that is not activated by
oxidation while is competent in DNA repair [81, 111, 113].
Interestingly, ROS may activate ATM independently of
MRN, indicating that the OS-activated form has a primary
role in redox sensing and signaling that may precede DNA
damage and does not depend on it. Thus, MRN is not essen-
tial for ATM activation by OS, as the ATM pathway may also
act separately from the DDR machinery. Evidences are
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known in which OS activation of ATM occurs in the absence
of DNA damage, and OS inhibits ATM activation by MRN
through disrupting the MRN-DNA complex [111]. This sug-
gests that the only OS-activated ATM may operate under
conditions of high ROS concentrations, playing a protective
defense against the oxidative damage. Indeed, ATM defi-
ciency is associated with elevated ROS, and ATM−/− cells
are more vulnerable to ROS-mediated OS, in comparison to
normal cells [81]. Moreover, ATM inhibition enhances the
sensitivity to the radiation therapy that generates ROS in can-
cer cells. The question is posed whether ATM may regulate
global cellular responses to OS. Interestingly, ATM is
activated in response to excessive ROS accumulation in ves-
sels where it stimulates the neoangiogenesis of the endothe-
lial cells by acting as a proangiogenic protein. The event is
not due to defects in DDR pathway, since it is realized
through a different signaling pathway from DDR, that is,
the oxidative activation of the mitogen-activated p38α
kinase. It is suggested that the pathological proliferating pro-
cesses might require the ROS defensive system induced by
OS activation of ATM. Targeting ATM might suppress
tumor angiogenesis and enhance the effect of antitumor
ROS-producing therapies. While loss of the activity of
MRN-activated ATM may enhance the mutagenic effects of
DDR ROS-sensitive
proteins
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Figure 3: Reactive oxygen species (ROS) generated by endogenous and exogenous agents cause DNA damage and activation of DNA damage
response (DDR). DDR activation arrests the cell cycle progression to repair DNA lesions and activate a program encoding ROS-sensitive
proteins involved in DDR. ATM, ATR, DNA-PKs, AMPK, Chk1, and Chk2 represent the sensors and transducers that coordinate DDR.
Their signals converge on effectors, as tumor suppressor p53, Cdc25 protein phosphatase, and WEE1 tyrosine kinase. DNA repair
pathways occur by several DNA repair enzymes such as DNA glycosylases, PARP1, AP endonuclease, ERCC1, MLH, and MSH. DDR
triggers apoptosis or necrosis when the DNA damage cannot be repaired. DDR-targeted proteins, whose inhibitors are currently in clinical
trials, are indicated in bold. snc-RNAs = small noncoding RNAs; lnc-RNAs = long noncoding RNAs; ATM= ataxia telangiectasia-mutated
protein; ATR=ATM- and Rad3-related; AMPK=AMP-activated protein kinase; CDK= cyclin-dependent kinase; DNA-PKcs = dependent
protein kinase catalytic subunit; PLK1 = polo-like kinase 1; WIP1 =wild-type p53-induced protein 1; PARP= poly (ADP-ribose)
polymerase; AP endonuclease = apurinic/apyrimidinic endonuclease; MLH=MutL homolog; MSH=MutS homolog.
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anticancer treatments and hamper the DDR barrier against
tumorigenesis, the inhibition of the OS-activated ATM activ-
ity, which mediates oxidative defenses, might be efficacious
in controlling malignant cell growth. The targeting of a cyste-
ine residue that is crucial to the ATM activation by OS is
believed a potential therapeutic strategy [21, 114]. Another
important finding that demonstrates the interplay between
ATM and OS is the ATM requirement for the ROS-
mediated repression of mTORC1 [115, 116]. In response to
elevated ROS, ATM activates the TSC2 tumor suppressor
through the LKB1/AMPK metabolic pathway in the cyto-
plasm to repress mTORC1 and induce autophagy. The path-
way acts as a node that integrates cell damage response with
key pathways involved in metabolism, protein synthesis, and
cell survival. The ATM interactor protein, ATMIN, is
involved in the OS-induced ATM activity together with the
SUMO (small ubiquitin-related modifier) enzymes as down-
stream ROS effectors, for cell survival under OS state.
Replacement of a SUMO enzyme with a variant fails to main-
tain activated the ATM-DDR pathway normally induced by
H2O2. The kinase ATR is also sensitive to modifications of
the redox asset, comprising modified O2 supply and OS con-
ditions. After being activated by replication inhibition during
hypoxia conditions, ATR phosphorylates the Chk1 check-
point signaling, p53, and histone γ-H2AX, activating the cell
cycle arrest and the stabilization of stalled replication forks
for allowing the subsequent reinitiation of the replication
process [110, 112]. Similarly, the ATR-Chk1 checkpoint sig-
naling is triggered by hyperoxic conditions in different
in vitro models: human dermal HDF fibroblasts, human
monocytes, lung adenocarcinoma cell line A549, and Xeno-
pus egg extracts. In A549 cell line, the Chk1 checkpoint sig-
naling is induced by ATR-mediated phosphorylation in an
ATM-independent fashion, while in human monocytes, the
ATM and ATR checkpoints are simultaneously activated by
ROS-induced DNA damage. Moreover, the antioxidant lyco-
pene, which is able to inhibit gastric pathologies related to
oxidative DNA damage as 8-OH-G and DSBs, is also able
to prevent ATM and ATR actions induced by ROS in gastric
epithelial AGS cells. In summary, OS-activated ATR may
precede OS-activated ATM operations showing that OS con-
ditions affect the ATR and ATM interplay in the DNA repair
pathways. How ATM and ATR checkpoint pathways regu-
late each other in response to OS remains to be elucidated
[110, 112]. The DNA-PKcs mentioned as basic DDR actors
are activated through their auto-phosphorylation by ROS
accumulation and stimulate a series of reactions in signaling
events typically triggered by OS, similarly to ATM. DNA-
PKcs play a direct role in repairing oxidative DNA lesion
through the BER repair pathways, although their mechanism
in response to OS has to be clarified. Investigations are devel-
oping to determine roles and coordination between ATM
and DNA-PKcs in OS signaling and oxidative DNA damage
repair under both physiological and pathological conditions.
This knowledge might offer new possibilities for the treat-
ment of ROS-related diseases, including cancer [110, 111].
Among ROS-sensitive proteins in DDR, Cdc25 phosphatases
(Cdc25s) and the checkpoint kinases CDKs are regulated by
the intracellular redox milieu. The balance between kinase
and phosphatase activity determines the strength of PI-3-
kinase/Akt signal that may be modified through favoring
kinase or phosphatase activity. Oxidations cooperate with
DDR signals to activate kinases and inactivate phosphatases
thus favoring the DNA repair. Cdc25s are direct OS targets
since oxidation of cysteine residues in their active sites cre-
ates intramolecular disulfides causing the enzyme inactiva-
tion; thereby the cell cycle is arrested until favorable
reducing conditions are restored. Cdc25s are inactivated by
both oxidation and phospho-degradation. While oxidation
is rapidly reverted, the phospho-degradation implies protein
synthesis to be reverted. An oxidizing environment may
increase the ratio between Cdc25 oxidation versus Cdc25
phospho-degradation, rendering the mitosis reenter easier
and ultimately pushing cells toward proliferation. Cdc25s
are overexpressed in tumor cells, which are generally
endowed with a prooxidant environment, thus providing a
mean for escape from the G2 arrest induced by the DNA
damage [117, 118]. Another molecule that acts as OS sensor
and cooperates with DDR is the tumor suppressor PTEN,
protein tyrosine phosphatases, whose gene results one of
the most frequently mutated genes in human cancers. PTEN
exerts its tumor suppressor activity by regulating cell growth
and survival through negative modulation of the P13-kinase/
Akt signaling pathway. PTEN loss and/or inactivation causes
abrogation of the checkpoint functions that control the cell
cycle thus impairing DNA repair and genomic stability of
the cells. Accumulation of DNA lesions andmutations causes
tumor promotion. PTEN is inactivated by ROS through for-
mation of an intramolecular disulfide bond between two cys-
teine residues that involves the protein active site. The
inactivated PTEN induces a signal pathway that begins from
Akt activation through phosphatidylinositol 3,4,5-trisphos-
phate, the PTEN physiological substrate, and terminates in
the activation of antioxidant enzymes, possibly being an
adaptive response to an oxidizing environment. The oxidized
asset generally present in cancer cells may inactivate PTEN
activity and, at the same time, allow for ROS acting as tumor
promoters [118, 119]. A functional interplay between DDR
pathways and DNA repair pathways occurs in response to
OS, as DDR pathways not only arrest cell cycle progression
but also directly participate in and facilitate DNA repair
pathways. DNA repair proteins may sense oxidative DNA
damage and process the damage into appropriate structures
for DDR activation. In conclusion, DDR and redox environ-
ment exert a subtle reciprocal interaction, since enzymes par-
ticipating to DDR are modulated by redox alterations and in
turn act to modulate the redox equilibrium. A link between
OS and PI-3-kinase/Akt pathway occurs in healthy as well
as in cancer cells in which represents an advantage to the
tumor survival [120, 121]. More intense investigations need
to understand the interplay between ATM/ATR-mediated
DDR pathways and DNA damage tolerance pathways in
OS response. It is unclear how ATM-Chk2 and ATR-Chk1
pathways crosstalk with each other in response to OS. The
new insights into ATM, ATR, and DNA-PKcs roles are a
stimulus to identify points that may be redox regulated thus
offering possibilities to treat ROS-related pathological condi-
tions and diseases [25, 28].
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5. Targeting DDR in Cancer Therapy
Anticancer treatments primarily target DNA damage, both
directly and indirectly, in consideration of its role in malig-
nant transformation and related consequences [15, 16]. The
potential existence of distinct DNA damage thresholds at
various stages of tumorigenesis and the role of the DDR path-
way in human cancers are developed by Khanna [97]. DDR is
rapidly induced, highly controlled, and regulated in cancer
cells as in healthy cells suggesting the possibility of targeting
definite DDR steps to hamper the cancer cell growth. The
overall proteins of the DDR machinery may provide target-
able intervention points for modulating DDR. It is worth-
while noticing that DDR protects and promotes cancer cell
survival through restoring their reparable lesions, also when
they are induced by DNA-targeted interventions. This event
represents a main route to generate resistance against a gen-
otoxic treatment. Dysregulation of DDR through missing or
defective canonical pathways in the DNA repair mechanisms
can lead to genomic instability that is a fundamental hall-
mark of cancer. Defective pathways may be eventually com-
pensated for other DDR pathways generating a context,
which highly favors cancer and resistance to genotoxic ther-
apies [17]. Indeed, only cancerous tissues, but not healthy tis-
sues, lack DDR components that render them dependent on
the remaining compensatory DDR pathways. These compen-
satory pathways allow for cancer cells surviving in the ROS
and replicative stress conditions that are present in cancer
tissues. Since the event is cancer-specific, strategies that tar-
get compensatory DDR pathways may render a treatment-
induced DNA damage more cytotoxic and preferentially
eliminate cancer cells, while minimizing the impact on
healthy cells. DDR inhibition has become an attractive ther-
apeutic concept in cancer therapy, also for preventing or
reversing the resistance to the anticancer treatments. [18,
122–126]. Indeed, dysregulated DDR is exploitable by both
ordinary therapy and DDR inhibitors. While upregulated
DDR confers resistance to DNA-damaging interventions
and has to be inhibited to overcome such refractoriness,
downregulated DDR makes tumor more susceptible to spe-
cific therapies and DDR inhibitors. In each single patient,
the balance between the DNA damage induced by a geno-
toxic treatment and the consequent DDR is responsible for
the effectiveness of the treatment. DNA repair-targeted ther-
apies exploit DNA repair defects in cancer cells to generate
their death resulting from simultaneous loss or inhibition of
two critical functions. For example, cancer cells defective in
one DNA repair pathway rely on alternate repair pathways,
if inhibition of a second repair pathway occurs then results
in cell death, an effect that selectively targets repair-
deficient cancer cells [127–130]. This type of intervention,
called synthetic lethality, is actually administered not only
to selectively inhibit DDR in cancer cells with deficiencies
in DNA repair pathway(s) but also to enhance chemotherapy
and radiotherapy efficacy. A number of highly selective
inhibitors that inhibit DNA repair pathways are in preclinical
development, while others are clinically administered as
DDR-targeted therapies in different stages of clinical evalua-
tion. Poly (ADP-ribose) polymerase (PARP) inhibitors
(PARPi) are the first clinically approved drugs designed to
exploit synthetic lethality in cancer therapeutics that are clin-
ically administered as DDR-targeted therapies to inhibit
DNA repair pathways [131, 132]. PARPs are a family of
DNA-dependent nuclear enzymes catalyzing the transfer of
ADP-ribose moieties from cellular nicotinamide-adenine-
dinucleotide to several proteins. This posttranslational mod-
ification is involved in cell response to DNA lesions, includ-
ing DNA damage recognition, signaling, and repair as well
as localized replication and transcriptional blockage, chro-
matin remodeling, and cell death induction. PARPs interact
directly/indirectly, or via PARylation with oncogenic pro-
teins and transcription factors, regulating their activity and
modulating the carcinogenesis. For instance, PARPs regulate
transcription factor-4 (ATF4) responsible for MAP kinase
phosphatase-1 (MKP-1), which regulates MAP kinases. Very
recent studies show that OS induces DNA breaks and PARP-
1 activation causing mitochondrial ROS production and cell
death. At the same time, PARPi reduce ROS-induced cell
death, suppress mitochondrial ROS production, and protect
mitochondrial membrane potential on an ATF4/MKP-1
dependent way, which inactivate JNK- and p38MAP kinases.
JNK is involved in the development of cancer stem cell, while
JNK inhibition reduces the stem cell ability in tumor initi-
ating. This could be a novel mechanism contributing to
beneficial PARPi effects in combinatory cancer therapy
with ROS-modulating drugs [133]. New therapeutic drugs
such as PARPi are examples of DDR-targeted therapies
that could potentially increase the DNA damage and repli-
cation stress imposed by platinum-based agents in tumor
cells and provide therapeutic benefit for patients with
advancedmalignancies [134]. Indeed, many therapies are less
effective by using one anticancer drug only, due to refractory
properties and drug resistance in advanced cancers. A con-
sensus is that anticancer drug cocktails might better control
cancer progresses and metastasis than single drug therapeu-
tics in clinical trials, but the complexity of drug combinations
is still a challenge [135]. Investigation on cell cycle check-
point signaling through ATM/ATR and pathways involved
in cancer onset and progression has led to discover potent
and selective ATM/ATR inhibitors that are actually in pre-
clinical and clinical development, respectively. Experimental
data have provided a strong rationale for administering ATR
inhibitors (ATRi) since they cause synthetic lethality in can-
cers characterized by deficiency of certain DDR components.
ATRi are assessed in clinical trials both as single agents and
in synergy with various chemo- and radiotherapy therapies,
including platinum, PARPi, and immune checkpoint inhibi-
tors [17, 124, 126]. Preclinical data highlight the chromatin-
bound phosphatase 2C isoform delta (WIP1) as potential tar-
get in human cancer. WIP1 is ubiquitously expressed at basal
levels and is potentiated by p53. It acts as a strong negative
regulator of p53 pathway thus forming a negative feedback
loop that allows for terminating p53 response when DNA
repair is completed. Genotoxic stress strongly induces
WIP1 in cell lines in a p53-dependent manner (the WIP1
name refers to wild-type p53-induced protein 1). The sub-
strate specificity of WIP1 matches the sites phosphorylated
by ATM as p53, γH2AX, and other DDR proteins. When
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overexpressed, WIP1 impairs p53 function and contributes
to tumorigenesis, usually in combination with other onco-
genes. WIP1 loss delays tumor development in mice, allows
reactivation of p53 pathway, and inhibits proliferation in
tumors endowed with p53. WIP1 is selectively inhibited by
the small-molecule GSK2830371 that efficiently reactivates
p53 pathway in various cancer types. In combination with
DNA damage-inducing chemotherapy or withMDM2 antag-
onists (such as nutlin-3), WIP1 inhibition promotes cancer
cell death or senescence, while healthy cells with basal WIP1
expression are relatively resistant to its inhibition [136].
6. Combinatory Anticancer Strategies Affecting
ROS Levels
Most conventional chemo- and radio-therapeutic agents kill
cancer cells in patients during cancer therapy by stimulating
ROS generation as, at least, one part of their mechanisms of
action [137]. ROS-inducing anticancer agents target mito-
chondria and enzymes in redox pathways resulting in OS
conditions that lead to cancer cell death. The mode of cell
death depends on the severity of the oxidative damage. Other
major mechanisms of these anticancer agents inhibit or dis-
able specific redox pathways and deplete reduced glutathione
(GSH) [138]. It is believed that continuous investigations will
allow the development of drug combinations for therapies
better tailored to patients that cause fewer side effects and
drug resistance [139]. Many cancer types may develop strong
antioxidant mechanisms and maintain higher ROS levels
than normal cells, but, at the same time, excessive OS levels
may have tumor-suppressive effects [140]. This aspect offers
an interesting therapeutic window because cancer cells might
result more sensitive than normal cells to agents that cause
further ROS accumulation. Examples of drugs with direct/
indirect effects on ROS that are effective in cancer therapies
are exemplified in the following sections in combination with
DDR inhibitors, basing on the drug function in the cells. For
better consulting of the drug combination, Table 1 shows
combinatory therapies basing on the DDR target in the cells.
Among the vast array of therapies, a single reference is
reported either in brackets or as clinical trial number from
https://clinicaltrials.gov/ (a database of privately and publicly
funded clinical studies conducted on cancer patients).
6.1. DDR Inhibitors and Alkylating-Intercalating Drugs
(Combinatory Therapies). Therapies based on platinum coor-
dination complexes (Pt-CC) as cisplatin (cDDP) [141–143],
carboplatin (CarboPt) [144], and others, as well as therapies
based on anthracyclines like doxorubicin, generate extremely
high ROS levels, which may cause tumor cell death by apo-
ptosis but also intolerable therapeutic side effects in the
patients. cDDP is an alkylating DNA-damaging agent widely
used as anticancer drug. It induces ROS via NADPH oxidase
(NOX) and involves, inter alia, the activation of Akt/mTOR
pathway, which is regulated by NOX-generated ROS [142,
145]. The combination of a large number of DDR inhibitors
with Pt-CC impairs the defensive response of tumor cells
against the Pt-CC-induced OS. For instance, the synergy
between cDDP and PARP inhibitors (PARPi) that hampers
the DNA damage repair may sensitize tumor cells to Pt-
CC-induced OS. These combinatory therapies not only
generate DNA damage foci and mitochondrial membrane
damage in non-small cell lung cancer cells (NSCLC cell
line) but also allow for reversing the resistance to the cDDP
when it is administered as single agent. Olaparib or veliparib
(PARPi) administration with Pt-CC is highly promising in
different phases of clinical trials against some cancer types.
Olaparib and cDDP administration in combination with
radiation therapy (RT), which induces a substantial increase
in ROS levels through NOXs activation [146], has been tested
in advanced non-small cell lung cancer (NSCLC) (http://
clinicaltrials.gov identifier: NCT01562210). In cancer treat-
ments unsuitable for Pt-CC-based therapy as the oesopha-
geal cancer, olaparib has been administered in combination
with RT (http://clinicaltrials.gov identifier: NCT01460888).
Veliparib and temozolomide [147] have been used to prevent
repair processes following the ROS damage generated by
CarboPt and paclitaxel [148] in metastatic breast cancer
(http://clinicaltrials.gov identifier: NCT01506609). Ruca-
parib (PARPi) has been administered with CarboPt to
advanced solid tumor patients (http://clinicaltrials.gov iden-
tifier: NCT01009190). A WEE kinase inhibitor, acting in
the DDR mechanism, has amplified the oxidative damage
induced by CarboPt, along with other cell killing actions,
(http://clinicaltrials.gov identifier: NCT02087176). The com-
pound MCI13E, which inhibits the replication protein A in
the DDR mechanism, has also been tested preclinically in
combination with cDDP [149]. A negative effect has been
observed in the combinatory therapy between B02IR
(RAD51 inhibitor) [150] with cDDP and mitomycin C
[151], in which the OS caused by cDDP and mitomycin C
results aggravated by B021R. Preclinical combinatory thera-
pies between drug-inducing ROS and DDR inhibitors to
overcome the resistance to Pt-drugs in solid tumors compre-
hend cDDP, NU-6027 (ATR inhibitor) [152], and hydroxy-
urea [153], among others, which is able to induce O2⨪
production. The DDR inhibitor VX-970 (ATR inhibitor)
sensitizes cancer cells to the combination of CarboPt and
the anticancer drug gemcitabine [154], which generates
ROS by NOX and via NF-κB activation in diverse cancer
types (http://clinicaltrials.gov identifier: NCT02627443).
Also, cDDP and gemcitabine have been administered with
VX-970 against metastatic cancer (http://clinicaltrials.gov
identifier: NCT02567409). Different DDR inhibitors, includ-
ing ATM inhibitors, have been administered in combination
with doxorubicin and other drugs to sensitize tumor cells to
doxorubicin-induced OS and DNA damage [155, 156].
Doxorubicin induces oxygen-derived free radicals, particu-
larly H2O2, through two main pathways: (i) a nonenzy-
matic pathway that utilizes iron and (ii) an enzymatic
mechanism that involves the mitochondrial respiratory
chain [157, 158]. Doxorubicin also inserts into DNA of
replicating cells and inhibits topoisomerase II, causing
double-strand DNA breaks and preventing DNA and
RNA synthesis [159]. In conditions of DNA-PKcs inhibition,
doxorubicin has been administered inside pegylated lipo-
somes against advanced solid tumors (http://clinicaltrials.
gov identifier: NCT02644278). Doxorubicin has also been
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Table 1: DNA damage response (DDR) inhibitors in combination with ROS-inducing treatments for cancer therapy.
DDR target DDR inhibitors ROS-inducing treatments (direct/indirect mode of action) References
Combinatory therapy
Preclinical studies
and clinical trials
PARP Olaparib
Radiotherapy OS increase by mitochondrial dysfunction [146] NCT01460888
Cisplatin +
Radiotherapy
ROS increase via NADPH oxidase [141–143] NCT01562210
(♦) (♦)
Cetuximab +
Radiotherapy
Glutamine transport inhibition, GSH decrease [163, 164] NCT01758731
(♦) (♦)
Erlotinib EGFR inhibition, ROS-mediated apoptosis [173, 174] [172]
PARP
Veliparib
(ABT-888)
Temozolomide +
Carboplatin +
Paclitaxel
ROS increase, AKT–mTOR signaling disruption [144] NCT01506609
ROS increase via NADPH oxidase [147]
ROS induction [148]
Bevacizumab ROS and apoptosis increase [165–167] NCT02305758
Rituximab CD20 binding in B-lymphocytes, O2
− generation [170, 171] [169]
Auranofin
H2O2 and ROS increase by thioredoxin
reductase inhibition
[191] [192]
Bortezomib ROS increase by ER stress
[178, 180,
181]
[179]
Lapatinib ROS increases [176] [176]
Berberine OS/NOS decrease [177] [177]
PARP Rucaparib Carboplatin (♦) (♦) NCT01009190
PARP
Niraparib Bevacizumab Cysteine and GSH level reduction [165–167] NCT02354131
4-Iodo-3-
nitrobenzamide
Buthionine
sulphoximine
Inhibition of glutamate–cysteine ligase
complex in GSH synthesis
[187–189] [190]
RPA MCI13E Cisplatin (♦) (♦) [149]
RAD51 B02IR
Mitomycin C+
Cisplatin
Stress-mediated ER cell apoptosis by ROS
generation
[151] [150]
(♦) (♦)
APE-1 Methoxyamine
Pemetrexed +
Cisplatin
Mitochondrial dysfunction, ROS increase [161] NCT02535312
(♦) (♦)
ATM KU-55933
Radiotherapy (♦) (♦) [155]
Doxorubicin +
Radiotherapy
ROS increase by enzymatic/nonenzymatic
pathways
[157] [156]
(♦) (♦)
ATR
NU-6027
Cisplatin (♦) (♦) [152]
Hydroxyurea Increased O2
− production [153] [152]
VX-970
Topotecan ROS increase [182] NCT02487095
Cisplatin +
Gemcitabine
(♦) (♦) NCT02567409
ROS increase, mitochondria alterations [154]
Carboplatin +
Gemcitabine
(♦) (♦) NCT02627443
(♦) (♦)
DNA-PKcs
NU-7441 Etoposide
ROS increase, GSH depletion,
mitochondrial alterations
[182, 183] [185]
KU-60648 Etoposide +
Doxorubicin
(♦) (♦)
[160]
(♦) (♦)
VX-984 Doxorubicin (♦) (♦) NCT02644278
UCN-01 5-Fluorouracile Cellular O2
•− increase (♦) NCT00045747
Chk1/Chk2 LY2603618
Pemetrexed (♦) (♦) NCT00988858
Cisplatin +
Pemetrexed
(♦) (♦) NCT01139775
(♦) (♦)
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combined with etoposide to concur with a dual inhibitor of
DNA-PKs and PI-3K to kill tumor cells by causing, inter alia,
mitochondria damage, GSHdepletion, andROS increase [160].
6.2. DDR Inhibitors and Folate Cycle Inhibitors (Combinatory
Therapies). Pemetrexed (PMX) and 5-FU are folate cycle
inhibitors that also promote cytochrome c release frommito-
chondria and interfere with the electron transport chain,
resulting in O2⨪ radical production and cell death [161,
162]. A DNA-PKcs inhibitor has been combined to 5-
fluorouracil (5-FU) to improve the survival of patients with
a form of metastatic pancreatic cancer that is refractory to
the anticancer drug gemcitabine (http://clinicaltrials.gov
identifier: NCT00045747). The cell reparatory response to
the injury caused by PMX and cDDP is prevented by the con-
temporary administration of methoxyamine, an inhibitor of
the DNA repairing AP endonuclease 1, thus resulting in a
major efficacy of the therapy (http://clinicaltrials.gov identi-
fier: NCT02535312). Prexasertib (LY2606368) inhibits the
Chk1 enzyme involved in the DDR mechanism and has been
tested in combination with 5-FU or PMX, or other drugs,
against advanced or diffuse metastatic cancer (http://
clinicaltrials.gov identifier: NCT02124148). PMX has been
administered with the DDR inhibitor LY2603618 (acting
against Chk1-Chk2) (http://clinicaltrial.gov identifier:
NCT00988858) and in combination with cDDP to improve
the survival of patients bearing advanced NSCLC (http://
clinicaltrials.gov identifier: NCT01139775).
6.3. DDR Inhibitors, Immuno-Oncology, and Targeted Agents
(Combinatory Therapies). Immunotherapy is experiencing a
growing interest as witnessed by the number of monoclonal
antibodies that are administered in tumor patients as single
agents or in combination with therapeutic interventions to
prevent resistance to specific drugs. The monoclonal anti-
body cetuximab, which targets the epidermal growth factor
(EGFR), has been combined with prexasertib (prevailing
Chk1 inhibitor) or cDDP (http://clinicaltrials.gov identifier:
NCT02555644) and the antifolates PMX or 5-FU, or other
drugs (http://clinicaltrials.gov identifier: NCT02124148).
Cetuximab downregulates the complex glutamine transporter
ASCT2-EGFR in the cell membrane of non-small cell lung
cancer cells (NSCLC cell lines). This causes that the gluta-
mine necessary for the cellular GSH synthesis decreases, as
well as the ROS reducing capacity of the cell. The consequent
GSH reduction and OS trigger apoptosis independently of
the EGFR-pathway downregulation [163, 164]. This
increased sensitivity to OS has been exploited in association
with the PARPi olaparib (http://clinicaltrials.gov identifier:
NCT01758731). The monoclonal antibody bevacizumab,
which causes cysteine and GSH level reduction and OS
increase [165–168], has been administered together with
the PARPi veliparib against metastatic colorectal cancer,
and together with the PARPi niraparib against ovarian can-
cer (http://clinicaltrials.gov identifier: NCT02305758 and
NCT02354131, resp.). The monoclonal antibody rituximab
specifically binds to the CD20 antigen of B-cells, causing cal-
cium influx into the cells and apoptotic signaling (reviewed
in [167]). The antibody has been associated with veliparib
against B-cell lymphoma [169]. In combination therapies,
the proapoptotic process induced by rituximab often syner-
gizes with the OS damage and O2
•− production caused by
traditional anticancer interventions [170, 171]. Regarding
targeted agents administered in combinatory strategies,
tyrosine kinase inhibitors (TKIs) can affect the cell redox
equilibrium in cancer cell lines and cancer tissues when
administered in association with DDR inhibitors [172–174].
For instance, erlotinib enhances ROS production and
induces ROS-mediated apoptosis in NSCLC A549 cell lines,
via activation of the JNK pathway, leading to epidermal
growth factor (EGFR) inhibition [173, 174]. Furthermore,
erlotinib causes Nox4-induced H2O2 production in head
and neck squamous cell cancer (HNSCC) cell lines [175].
The association between the TKIs erlotinib and gefitinib is
approved for non-small cell lung cancer (NSCLC) treatment
in tumors with specific EGFR mutations (10–15% of Cauca-
sian patients). The TKi lapatinib is the only TKI approved for
treating the human breast cancer subtype overexpressing the
HER2 oncogene (20–30% of breast cancers). Lapatinib in
combination with ABT-888 (PARPi) augments the cytotox-
icity to ABT-888 resulting in efficacious synthetic lethality
in HER2-positive breast cancer cells in vitro and in vivo
Table 1: Continued.
DDR target DDR inhibitors ROS-inducing treatments (direct/indirect mode of action) References
Combinatory therapy
Preclinical studies
and clinical trials
Prexasertib
(LY2606368)
Cisplatin +
Cetuximab +
Pemetrexed +
5-Fluorouracile
(♦) (♦) NCT02124148
(♦) (♦)
(♦) (♦)
(♦) (♦)
Cisplatin +
Radiotherapy +
Cetuximab
(♦) (♦) NCT02555644
(♦) (♦)
(♦) (♦)
APE1 =AP endonuclease 1; ATM= ataxia telangiectasia-mutated protein; ATR =ATM- and Rad3-related; CHK = checkpoint kinase; DNA-PKcs = DNA-
dependent protein kinase catalytic subunit; PARP = poly (ADPribose) polymerase; RPA = replication protein A. References in brackets; clinical trial
identifiers (NCT). The effect of the single ROS-inducing drugs is indicated one time, and the following times is indicated with (♦).
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[176]. Interestingly, the combination of lapatinib and the
anticancer plant-derived berberine allows for reversing lapa-
tinib resistance through the modulation of the ROS level
[177]. In addition, a lapatinib analogue leads to ROS increase
in the treatment of inflammatory breast cancer (reviewed in
[167]). As a different example of targeted agents, bortezomib
is the first ubiquitin-proteasome inhibitor approved as anti-
cancer drug for human use [178]. This compound generates
OS and aggravates the endoplasmic reticulum stress, causing
apoptotic protein accumulation. Bortezomib has been pro-
posed in association with ABT-888 (PARPi) [179–181].
6.4. DDR Inhibitors and Inhibitors of Topoisomerases I and II
(Combinatory Therapies). Inhibitors of topoisomerases I and
II, such as topotecan and etoposide, cause single- and double-
strand DNA breaks which inhibit DNA function and ulti-
mately lead to cell death. These inhibitors induce OS essen-
tially by increasing the endoplasmic reticulum stress and
the oxidative status, as revealed by increased lipid and pro-
tein oxidation and decreased GSH and sulfhydryl levels in
cancer lines [182, 183]. Evaluation of the chemotherapy
improvement of topotecan action along with the drug VX-
970 (ATR inhibitor) has been proposed (http://clinicaltrials.
gov identifier: NCT02487095). In addition, the enhanced
effectiveness of the combination between NU-7441 (DNA-
PKcs inhibitor) [184] and etoposide [185], as well as KU-
60648 (adual inhibitorofDNA-PKandPI-3K)with etoposide
and doxorubicin, has been reported [160].
6.5. DDR Inhibitors and Direct Inhibitors of the Redox System
(Combinatory Therapies). It is well known that elevated GSH
levels trigger chemo-resistance in cancer cells through differ-
ent pathways: (i) direct interaction with drugs and ROS, (ii)
prevention of damage of protein andDNA, and (iii) induction
of DNA repair [186]. Several approaches for blocking GSH
synthesis in cancer cells have been attempted, but, at the same
time, cancer cells with high GSH content are more sensitive to
drugs that affect GSH metabolism than normal cells. Buthio-
nine sulphoximine (BSO) is the classical inhibitor of the
rate-limiting enzyme in GSH synthesis that is used to increase
cancer cell sensitivity to chemotherapeutics [187–189]. To
this aim, the combination of 4-I-3 nitrobenzamide (PARPi)
withBSOhas been investigated in theE-ras 20 cancer cells that
express the RAS oncogene, reporting enhanced cell killing
[190]. Similarly, to GSH, changes to thioredoxin (Trx)metab-
olism are implicated in tumor cell resistance to chemotherapy.
The gold compound auranofin (AF) is used as Trx inhibitor to
induce OS, endoplasmic reticulum stress, and apoptosis in
many tumor types, including cisplatin-resistant human ovar-
ian cancer cells [191]. Cotreatment of mantle cell lymphoma
(MCL) cells with AF and ABT-888 (PARPi) increases syner-
gistically the apoptosis of ATM-proficient MCL cells, with
increased γ-H2AX foci induction in the DNA and depletion
of p-Chk1 (a downstream target of ATR signaling) [192].
7. Conclusions and Perspectives
The EU-ROS consortium comprising more than 140 mem-
bers has worked for four years on the main topics of the
redox biology and medicine. The results obtained highlight
how synergistic approaches combining a variety of diverse
and contrasting disciplines are needed in order to advance
the knowledge of redox-associated diseases, including cancer
[193]. ROS act as messengers that coordinate intracellular
redox signaling in physiological and biological responses, as
well as in tumorigenesis, suggesting that ROS-activated
oncogenic pathways may also be regulated. Many strategies
are under clinical investigations and trials that target the
redox adaptation of cancer cells by redox-modulating inter-
ventions to both overcome drug resistance and eliminate
selectivity cancer cells. Clinical efficacy of anticancer chemo-
therapies is dramatically hampered by drug resistance depen-
dent on inherited traits, acquired defense against toxins, and
adaptive mechanisms mounting in tumors. A heterogeneous
cell population with distinct tumorigenic capabilities that
complicate and limit the anticancer treatments may compose
cancer tissues. Cancer plasticity leads to develop drug resis-
tance by distinct mechanisms: (i) mutations in the target,
(ii) reactivation of the targeted pathway, (iii) hyperactivation
of alternative pathways, and (iv) cross-talk with the microen-
vironment. Molecular events leading to drug resistance are
regulated by redox mechanisms suggesting redox-active
drugs (antioxidants and prooxidants) or inhibitors of the
inducible antioxidant defense as a novel approach to dimin-
ish the drug resistance. Repair and maintenance of cell
genome stability show the cooperation between molecules
that are essential to DDR and molecules essential to maintain
the redox equilibrium. Ever increasing evidences highlight
how the intricate molecular cross-talks between DDR and
OS, generally indicated as OS-induced DDR pathways, can
provide a useful insight into the drug discovery research
aimed at counteracting cancer cell growth. Targeting DNA
repair machinery has been a hot topic in anticancer therapy
in the last decades. In fact, DDR inhibitors have been devel-
oped to increase the efficacy of conventional therapies and
utilized in combinatory therapy with common cancer treat-
ment, to overcome the therapeutic resistance to DNA-
damaging chemotherapy and radiotherapy. This strategy
can be used to selectively kill cancer cells with deficiencies
in special DNA repair pathway(s) based on the concept of
synthetic lethality. Although targeting DDR pathways is
believed a promising therapy to fight solid and hematologic
cancers, first early clinical trials with inhibitors in monother-
apy have obtained scarce success. Currently, in order to
optimize the application of these DDR inhibitors in the com-
binatory therapies overcoming resistance, massive array of
preclinical and clinical trials are evaluating combinations of
DDR inhibitors in targeted therapies. The best way to get a
personalized medicine, matching the right treatment to the
right patient, is based on identifying which patients have
which DDR defect. The recent next generation sequencing
(NGS) technology, which allows whole genomes to be
sequenced in days, will be helpful to this strategy [194].
Today, an ever increasing range of available inhibitors target-
ing major DDR pathways allows for combining the inhibitors
each other and with other targeted therapies and with treat-
ments such as chemotherapy and radiotherapy, aiming at
eliminating any escape road for cancer cells. In addition,
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there is an emerging impact of the promising immuno-
oncology therapies as a new tumor treatment that might
synergize with DDR inhibitions [http://clinicaltrials.gov
identifier: NCT02484404] [195]. Recently, even the modula-
tion of OS has been considered as a strategy that may affect
some DDR pathways in human cancer and the responses to
new anticancer therapies. For example, combinatory treat-
ments between DDR inhibitors and agents that regulate indi-
rectly or directly OS are very encouraging. The importance of
this therapeutic strategy is supported by the results obtained
from several ongoing preclinical and clinical studies exploit-
ing combinations between DDR inhibitors and drugs that
modify the ROS homeostasis (Table 1). The complexity of
emerging categories of drugs targeting DDR and new strate-
gies for integrating DNA repair-targeted therapies into clini-
cal practice, including combination regimens, is a continuous
challenge for both scientist and patients. Indeed, some cau-
tion are necessary for DNA repair-targeted agents as treat-
ment with DNA repair inhibitors could increase mutation
rates in malignant cells, leading to evolution of metastatic
properties and/or drug resistance. Also, systemic DNA dam-
age could increase the risk of secondary malignancies. While
maximizing the cellular dependency on DDR inhibition
often requires an oxidative DNA damage insult by chemo-
therapy or radiation, different levels of ROS and enzymes
involved in their metabolism can participate in the DDR sig-
naling. They can modulate the activity of key DDR enzymes
and regulate the stringency of DDR by rendering the cancer
cells more sensible to DDR inhibitors. Thus, lower doses of
DDR target therapies might be administered to the patients.
At the same time, the capacity of some chemotherapeutic
agents to cause temporary perturbations in ROS levels can
offer a therapeutic opportunity to both treat cancer and mit-
igate some toxic side effects of the chemotherapeutic agents.
It is believed that the combination of ROS-affecting drugs
with DDR inhibitors may help to define better-tailored ther-
apies with fewer side effects and lower probabilities to pro-
mote drug resistance development.
Abbreviations
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